Loading…
Underlying
Underlying Price
$8.34
Type
Put
Strike
9.5
Expiration
Oct 30, 2026
DTE
10d
Moneyness
ITM
Intrinsic
$1.16
IBRX 9.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.55 | +83.33% | 76 | 438 |
| Oct 30, 2026 | 10d | $0.75 | +50.00% | 39 | 300 |
| Nov 6, 2026 | 17d | $1.10 | +48.65% | 2 | 80 |
| Nov 13, 2026 | 24d | $1.14 | +26.67% | 20 | 24 |
| Nov 27, 2026 | 38d | $1.13 | +7.62% | 1 | 17 |
IBRX Nearby Strikes · Oct 30, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 6.5 P | $0.05 | -85.71% | 5 | 18 | OTM |
| 7 P | $0.05 | -50.00% | 1 | 78 | OTM |
| 7.5 P | $0.12 | -40.00% | 1 | 62 | OTM |
| 8 P | $0.25 | +92.31% | 2 | 150 | OTM |
| 8.5 P | $0.35 | +75.00% | 33 | 1,052 | ITM |
| 9 P | $0.50 | +72.41% | 53 | 599 | ITM |
| 9.5 P | $0.75 | +50.00% | 39 | 300 | ITM |
| 10 P | $1.15 | +76.92% | 2 | 259 | ITM |
| 10.5 P | $1.32 | +7.32% | 1 | 54 | ITM |
| 11 P | — | — | 0 | 0 | ITM |
| 11.5 P | $1.98 | +30.26% | 5 | 6 | ITM |
| 12 P | — | — | 0 | 0 | ITM |
| 12.5 P | — | — | 0 | 0 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.